The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
暂无分享,去创建一个
[1] M. Weiner,et al. Relationships between biomarkers in aging and dementia , 2009, Neurology.
[2] Clifford R. Jack,et al. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons , 2014, Neurobiology of Aging.
[3] Keith A. Johnson,et al. Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly , 2011, Annals of neurology.
[4] Benjamin J. Shannon,et al. Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.
[5] W. M. van der Flier,et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints , 2013, Neurology.
[6] Prashanthi Vemuri,et al. Effect of APOE ε4 status on intrinsic network connectivity in cognitively normal elderly subjects. , 2011, Archives of neurology.
[7] A. Joshi,et al. Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ Study , 2013, Alzheimer's & Dementia.
[8] B. Hyman,et al. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. , 2011, Archives of neurology.
[9] Denise C. Park,et al. &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.
[10] Prevalence Estimates for Latent Neurodegenerative Disease , 2011, Toxicologic pathology.
[11] Trey Hedden. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden , 2010, Alzheimer's & Dementia.
[12] Olivier Salvado,et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. , 2010, Brain : a journal of neurology.
[13] J. Schneider,et al. Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.
[14] C. Rowe,et al. Rapid decline in episodic memory in healthy older adults with high amyloid-β. , 2013, Journal of Alzheimer's disease : JAD.
[15] E. Leitersdorf,et al. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. , 1995, The American journal of cardiology.
[16] Basavaraj Hooli,et al. A three-dimensional human neural cell culture model of Alzheimer’s disease , 2014, Nature.
[17] C. Rowe,et al. Aβ amyloid, cognition, and APOE genotype in healthy older adults , 2013, Alzheimer's & Dementia.
[18] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[19] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[20] Paul Maruff,et al. Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease , 2013, Alzheimer's & Dementia.
[21] H. Soininen,et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.
[22] W. Jagust,et al. Association of lifetime cognitive engagement and low β-amyloid deposition. , 2012, Archives of neurology.
[23] Ole A. Andreassen,et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.
[24] J. Morris,et al. The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.
[25] A. Tales,et al. To revitalize neurology we need to address physician burnout , 2015, Neurology.
[26] Reisa A. Sperling,et al. Face-name associative memory performance is related to amyloid burden in normal elderly , 2011, Neuropsychologia.
[27] V. Calhoun,et al. Default mode network connectivity in stable vs progressive mild cognitive impairment , 2011, Neurology.
[28] Mark A Mintun,et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.
[29] L. Ozmen,et al. Combined Treatment with a BACE Inhibitor and Anti-Aβ Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice , 2014, The Journal of Neuroscience.
[30] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[31] Hyoung-Gon Lee,et al. Challenging the Amyloid Cascade Hypothesis: Senile Plaques and Amyloid‐β as Protective Adaptations to Alzheimer Disease , 2004, Annals of the New York Academy of Sciences.
[32] H. Hampel,et al. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. , 2007, Brain : a journal of neurology.
[33] Francisco Lopera,et al. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease , 2010, Annals of neurology.
[34] Clifford R Jack,et al. Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.
[35] Bradley T. Hyman,et al. Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.
[36] V. Calhoun,et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease , 2007, Proceedings of the National Academy of Sciences.
[37] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[38] D. Head,et al. Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly , 2010, Biological Psychiatry.
[39] Michael Meaney,et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits , 1998, Nature Neuroscience.
[40] A. Fagan,et al. Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. , 2013, JAMA neurology.
[41] R. Sperling,et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline , 2010, Neurology.
[42] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[43] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[44] Nick C Fox,et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.
[45] A. Convit,et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits , 1998, Nature Neuroscience.
[46] Yaakov Stern,et al. Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review , 2013, Alzheimer's Research & Therapy.
[47] A. Fagan,et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.
[48] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.
[49] S. Paul,et al. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms , 2007, Neurobiology of Aging.
[50] C. Jack,et al. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.
[51] Val Lowe,et al. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. , 2013, Brain : a journal of neurology.
[52] R. Sperling,et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.
[53] Keith A. Johnson,et al. Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.
[54] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[55] Reisa A. Sperling,et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals , 2012, Neuropsychologia.
[56] Philip S. Insel,et al. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment , 2015, Neurobiology of Aging.
[57] Richard Hollister,et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.
[58] Richard B. Buxton,et al. Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups , 2009, NeuroImage.
[59] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[60] Naruhiko Sahara,et al. Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.
[61] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[62] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.
[63] L. Ferrucci,et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB , 2010, Neurology.
[64] L. Kuller,et al. Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia , 2013, Neurology.
[65] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[66] Abraham Z Snyder,et al. Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging , 2014, Neurology.
[67] C. Sorg,et al. Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease , 2014, Alzheimer's & Dementia.
[68] P. Snyder,et al. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease , 2013, Neurobiology of Aging.
[69] C. Jack,et al. MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.
[70] D. Wilkin,et al. Neuron , 2001, Brain Research.
[71] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[72] Vince D. Calhoun,et al. Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer's Disease: An Independent Component Analysis , 2006, The Journal of Neuroscience.
[73] J. Karlawish,et al. The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.
[74] C. Rowe,et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.
[75] Miranka Wirth,et al. Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not β-Amyloid in Cognitively Normal Older Individuals , 2013, The Journal of Neuroscience.
[76] J. Morris. Dominantly inherited Alzheimer network (DIAN): Overview, aims and progress , 2011, Alzheimer's & Dementia.
[77] J. Price,et al. Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.
[78] Cindee M. Madison,et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. , 2013, JAMA neurology.
[79] R. Sperling,et al. Functional MRI of mnemonic networks across the spectrum of normal aging, mild cognitive impairment, and Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[80] A. Fagan,et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.
[81] Shaomin Li,et al. Environmental Novelty Activates β2-Adrenergic Signaling to Prevent the Impairment of Hippocampal LTP by Aβ Oligomers , 2013, Neuron.
[82] Keith A. Johnson,et al. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. , 2014, JAMA neurology.
[83] E. Mandelkow,et al. Tau in Alzheimer's disease. , 1998, Trends in cell biology.
[84] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[85] C. Jack,et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.
[86] Eric M Reiman,et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study , 2012, The Lancet Neurology.
[87] Kelly O'Keefe,et al. Hippocampal Hyperactivation Associated with Cortical Thinning in Alzheimer's Disease Signature Regions in Non-Demented Elderly Adults , 2011, The Journal of Neuroscience.
[88] Cindee M. Madison,et al. Neural compensation in older people with brain β-amyloid deposition , 2014, Nature Neuroscience.
[89] Ahmad R. Hariri,et al. Interleukin-6 Covaries Inversely with Hippocampal Grey Matter Volume in Middle-Aged Adults , 2008, Biological Psychiatry.
[90] Keith A. Johnson,et al. Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.
[91] C. Jack,et al. Effect of lifestyle activities on alzheimer disease biomarkers and cognition , 2012, Annals of neurology.
[92] Kewei Chen,et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.
[93] L. Mucke,et al. Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.
[94] Faith M. Gunning-Dixon,et al. Aging, sexual dimorphism, and hemispheric asymmetry of the cerebral cortex: replicability of regional differences in volume , 2004, Neurobiology of Aging.
[95] George Jewell,et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study , 2014, Molecular Psychiatry.
[96] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[97] Gaël Chételat,et al. Alzheimer disease: Aβ-independent processes—rethinking preclinical AD , 2013, Nature Reviews Neurology.
[98] Shauna M. Stark,et al. A task to assess behavioral pattern separation (BPS) in humans: Data from healthy aging and mild cognitive impairment , 2013, Neuropsychologia.
[99] K. Jellinger,et al. Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.
[100] N. Filippini,et al. Distinct patterns of brain activity in young carriers of the APOE e4 allele , 2009, NeuroImage.
[101] M. Mintun,et al. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. , 2008, Archives of neurology.
[102] J. Gunter,et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.
[103] Chengjie Xiong,et al. Impaired default network functional connectivity in autosomal dominant Alzheimer disease , 2013, Neurology.
[104] Philip S. Insel,et al. Emerging β-amyloid pathology and accelerated cortical atrophy. , 2014, JAMA neurology.
[105] Michael D. Greicius,et al. Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. , 2011, Cerebral cortex.
[106] C. Jack,et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. , 2013, JAMA neurology.
[107] Wei Zhang,et al. A highly selective and specific PET tracer for imaging of tau pathologies. , 2012, Journal of Alzheimer's disease : JAD.
[108] Yaakov Stern,et al. Cognitive Reserve: Implications for Assessment and Intervention , 2013, Folia Phoniatrica et Logopaedica.
[109] Keith A. Johnson,et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline , 2012, Neurology.
[110] Keith A. Johnson,et al. Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals , 2013, Neurobiology of Aging.
[111] C. Duyckaerts,et al. Prevalence, Incidence and Duration of Braak’s Stages in the General Population: Can We Know? , 1997, Neurobiology of Aging.
[112] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[113] Christos Davatzikos,et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition , 2014, Acta neuropathologica communications.
[114] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[115] Nick C Fox,et al. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42 , 2010, Annals of neurology.
[116] Menno P. Witter,et al. Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.
[117] Bradley T. Hyman,et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.
[118] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[119] Keith A. Johnson,et al. Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.
[120] William J Jagust,et al. Estrogen- and tamoxifen-associated effects on brain structure and function , 2004, NeuroImage.
[121] Steven Mennerick,et al. Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.
[122] C R Jack,et al. Spotlight on the January 24 Issue , 2012, Neurology.
[123] Clifford R. Jack,et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?☆ , 2013, NeuroImage: Clinical.
[124] Keith A. Johnson,et al. Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.
[125] Sebastien Ourselin,et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. , 2014, JAMA neurology.
[126] F. Schmitt,et al. Self-reported memory complaints , 2014, Neurology.
[127] A. Dale,et al. What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus , 2014, Progress in Neurobiology.
[128] H. Hampel. Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. , 2012, Journal of Alzheimer's disease : JAD.
[129] Keith A. Johnson,et al. Functional Alterations in Memory Networks in Early Alzheimer’s Disease , 2010, NeuroMolecular Medicine.
[130] W. Klein,et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. , 2006, The Journal of biological chemistry.
[131] David T. Jones,et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.
[132] Alan C. Evans,et al. Neuronal Networks in Alzheimer's Disease , 2009, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[133] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[134] D. Bennett,et al. TDP-43 pathology, cognitive decline, and dementia in old age. , 2013, JAMA neurology.
[135] L. Hebert,et al. Cognitive activity and the cognitive morbidity of Alzheimer disease , 2010, Neurology.
[136] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[137] David M Holtzman,et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. , 2005, Neuron.
[138] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[139] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[140] Jurgen Fripp,et al. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. , 2013, JAMA neurology.
[141] Kristen M. Kennedy,et al. Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan , 2012, NeuroImage.
[142] C. Rowe,et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. , 2014, Brain : a journal of neurology.
[143] Elizabeth C Mormino,et al. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. , 2012, Archives of neurology.
[144] John L. Robinson,et al. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. , 2010, Archives of neurology.
[145] W. Klunk,et al. Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. , 2014, Brain : a journal of neurology.
[146] C. Rowe,et al. Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.
[147] Zeshan Ahmed,et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity , 2014, Acta Neuropathologica.
[148] H. Braak,et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.
[149] A. Dale,et al. Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. , 2012, Archives of neurology.
[150] David Bartrés-Faz,et al. Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.
[151] Keith A. Johnson,et al. Amyloid Deposition Is Linked to Aberrant Entorhinal Activity among Cognitively Normal Older Adults , 2014, The Journal of Neuroscience.
[152] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[153] W. Klein,et al. Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.
[154] Clifford R. Jack,et al. Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration , 2014, Neurology.
[155] A. Fagan,et al. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. , 2011, Archives of neurology.
[156] T. Montine,et al. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. , 2014, JAMA neurology.
[157] D. Bennett,et al. Life-span cognitive activity, neuropathologic burden and cognitive aging , 2013, Alzheimer's & Dementia.
[158] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.
[159] Florence Pasquier,et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? , 2002, Experimental Gerontology.
[160] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[161] Suzanne E. Welcome,et al. Mapping cortical change across the human life span , 2003, Nature Neuroscience.
[162] A. Fagan,et al. Functional connectivity and graph theory in preclinical Alzheimer's disease , 2014, Neurobiology of Aging.
[163] Dominic Holland,et al. Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau , 2011, Annals of neurology.
[164] Shaomin Li,et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.
[165] J. Morris,et al. Functional deactivations: Change with age and dementia of the Alzheimer type , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[166] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[167] M N Rossor,et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. , 2013, Revue neurologique.
[168] M. Greicius,et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.
[169] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[170] Kelly O'Keefe,et al. Evidence of Altered Posteromedial Cortical fMRI Activity in Subjects at Risk for Alzheimer Disease , 2010, Alzheimer disease and associated disorders.
[171] William J. Jagust,et al. Lifespan brain activity, β-amyloid, and Alzheimer's disease , 2011, Trends in Cognitive Sciences.
[172] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[173] Rebecca A Betensky,et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease , 2014, Neurology.
[174] C. Sorg,et al. Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease , 2014, Alzheimer's & Dementia.
[175] J. Morrison,et al. Life and death of neurons in the aging brain. , 1997, Science.